Cue Biopharma, Inc. | Business Contracts

Registration Rights Agreement, dated November 14, 2022, by and among the Company and the other parties thereto (Filed With SEC on November 15, 2022)

Termination of License Agreement, dated September 9, 2022, between Cue Biopharma, Inc. and MIL 21E, LLC (Filed With SEC on November 14, 2022)

Rider to License Agreement, dated as of July 7, 2022, between Cue Biopharma, Inc. and MIL 40G, LLC (Filed With SEC on August 4, 2022)

Director Compensation Policy dated January 1, 2021 (Filed With SEC on May 10, 2022)

Open Market Sale AgreementSM, dated October 1, 2021, by and between Cue Biopharma, Inc. and Jefferies LLC (Filed With SEC on November 9, 2021)

Form of Securities Purchase Agreement, dated November 14, 2022, by and among the Company and the other parties thereto (Filed With SEC on November 15, 2022)

Form of Warrant to Purchase Common Stock or Pre-Funded Warrant to be issued pursuant to the Securities Purchase Agreement (Filed With SEC on November 15, 2022)

Form of Pre-Funded Warrant to Purchase Common Stock to be issued pursuant to the Securities Purchase Agreement (Filed With SEC on November 15, 2022)

First Amendment to the License Agreement, dated May 3, 2022, between Cue Biopharma, Inc. and MIL 40G, LLC (Filed With SEC on August 4, 2022)

License Agreement, March 28, 2022 (Filed With SEC on March 30, 2022)

Loan and Security Agreement, dated February 15, 2022, by and between Cue Biopharma, Inc. and Silicon Valley Bank (Filed With SEC on March 16, 2022)

Consulting Agreement, dated January 1, 2017, between the Registrant and Ken Pienta, as amended by Amendment No. 1 to Consulting Agreement dated December 15, 2021 (Filed With SEC on March 16, 2022)

Third Amendment to License Agreement, dated October 22, 2021, by and between Cue Biopharma, Inc. and MIL 21E, LLC (Filed With SEC on November 9, 2021)

Open Market Sale AgreementSM, dated October 1, 2021, by and between Cue Biopharma, Inc. and Jefferies LLC (Filed With SEC on October 1, 2021)

Eighth Amendment to Collaboration, License and Option Agreement, dated December 7, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

First Amendment to the Amended and Restated License Agreement with Albert Einstein College of Medicine dated October 30, 2018 (Filed With SEC on March 9, 2021)

First Amendment to the Exclusive Patent License and Research Collaboration Agreement with Merck Sharp & Dohme Corp. dated November 9, 2020 (Filed With SEC on March 9, 2021)

Third Amended and Restated Executive Employment Agreement dated March 4, 2021 between the Company and Daniel Passeri (Filed With SEC on March 9, 2021)

Seventh Amendment to Collaboration, License and Option Agreement, dated May 14, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

Sixth Amendment to Collaboration, License and Option Agreement, dated February 14, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

Fifth Amendment to Collaboration, License and Option Agreement, dated January 10, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

Fourth Amendment to Collaboration, License and Option Agreement, dated December 18, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

Third Amendment to Collaboration, License and Option Agreement, dated October 29, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

Second Amendment to Collaboration, License and Option Agreement, dated August 5, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

First Amendment to Collaboration, License and Option Agreement, dated March 15, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

Third Amendment to Vivarium Agreement, dated July 20, 2020, between the Registrant and MIL 21E, LLC (Filed With SEC on November 9, 2020)

Executive Employment Agreement dated August 21, 2020 between the Company and Kerri-Ann Millar (Filed With SEC on August 24, 2020)

Second Amendment to License Agreement between the Registrant and MIL 21E, LLC (Filed With SEC on June 26, 2020)

At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated June 22, 2020 (Filed With SEC on June 22, 2020)

At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated March 27, 2020 (Filed With SEC on March 27, 2020)

Amendment No. 1 to Cue Biopharma, Inc. 2016 Omnibus Incentive Plan (Filed With SEC on March 12, 2020)

Description of Common Stock of the Registrant Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 12, 2020)

Second Amended and Restated Executive Employment Agreement dated February 10, 2020 between the Company and Daniel Passeri (Filed With SEC on February 10, 2020)

At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated November 25, 2019 (Filed With SEC on November 26, 2019)

Amended and Restated Executive Employment Agreement dated October 3, 2019 between the Company and Anish Suri (Filed With SEC on October 7, 2019)

Amended and Restated Executive Employment Agreement dated October 3, 2019 between the Company and Daniel Passeri (Filed With SEC on October 7, 2019)

At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated June 5, 2019 (Filed With SEC on June 5, 2019)

Director Compensation Policy dated October 30, 2018 (Filed With SEC on March 14, 2019)

Cue Biopharma, Inc. (38)